Bernardo Matos da Cunha

Bernardo Matos da Cunha

Auto-generated profile, based on publicly available information

Bernardo Matos da Cunha

Hospital Sarah, Brasília

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2015 in Autoimmunity Reviews
Verified
Journal Article
Closed access
BCBernardo M. Cunha
Bernardo M. Cunha
LMLicia Maria H. Mota
Licia Maria H. Mota
GSGecilmara Salviato
Gecilmara Salviato
ISIzabella P. Safe
Izabella P. Safe
MLMarcus Vinícius Guimarães de Lacerda
Marcus Vinícius Guimarães de Lacerda

18 February 2011 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
GLGabriela Lannes
Gabriela Lannes
FEFernanda R. Elias
Fernanda R. Elias
BCBernardo Cunha
Bernardo Cunha
NJNilson Jesus
Nilson Jesus
EKEvandro M. Klumb
Evandro M. Klumb
FRFrancinne M. Ribeiro
Francinne M. Ribeiro

1 October 2016 in Gait & Posture
Verified
Journal Article
Closed access
BCBernardo Matos da Cunha
Bernardo Matos da Cunha
AGAline Dalfito Gava
Aline Dalfito Gava
SOSandro Barbosa de Oliveira
Sandro Barbosa de Oliveira
ADAna Cristina de David
Ana Cristina de David
LSLeopoldo Luiz dos Santos-Neto
Leopoldo Luiz dos Santos-Neto

19 April 2022 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
LVLuciana Pinto Valadares
Luciana Pinto Valadares
BFBruno Silva de Araújo Ferreira
Bruno Silva de Araújo Ferreira
BCBernardo Matos da Cunha
Bernardo Matos da Cunha
LMLarissa Aniceto Moreira
Larissa Aniceto Moreira
FBFrederico Gideoni Albinati Batista
Frederico Gideoni Albinati Batista
GMGabriel Galvão Rafael Magalhães
Gabriel Galvão Rafael Magalhães
Objective: Fibrous dysplasia (FD) is a rare bone disorder that can involve any part of the skeleton, leading to bone pain, deformities, and fractures. Treatment with intravenous bisphosphonates has been used with variable results. Therefore, we aimed to evaluate the effects of zoledronic acid (ZA) therapy in patients with monostotic or polyostotic FD. Subjects and methods: The medical records of thirteen patients with FD evaluated between 2015 and 2020 were retrospectively analyzed. In the subgroup of patients treated with [...] ABSTRACT Objective: Fibrous dysplasia (FD) is a rare bone disorder that can involve any part of the skeleton, leading to bone pain, deformities, and fractures. Treatment with intravenous bisphosphonates has been used with variable results. Therefore, we aimed to evaluate the effects of zoledronic acid (ZA) therapy in patients with monostotic or polyostotic FD. Subjects and methods: The medical records of thirteen patients with FD evaluated between 2015 and 2020 were retrospectively analyzed. In the subgroup of patients treated with

1 September 2021 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
BBBonnie L. Bermas
Bonnie L. Bermas
MGMilena Gianfrancesco
Milena Gianfrancesco
HTHelen Tanner
Helen Tanner
ASAndrea M. Seet
Andrea M. Seet
MAMathia C. Aguiar
Mathia C. Aguiar
PRPhilip C. Robinson
Philip C. Robinson
Objective: To describe coronavirus disease 2019 (COVID-19) and pregnancy outcomes in patients with rheumatic disease who were pregnant at the time of infection.Methods: Since March 2020, the COVID-19 Global Rheumatology Alliance has collected cases of patients with rheumatic disease with COVID-19. We report details of pregnant women at the time of COVID-19 infection, including obstetric details separately ascertained from providers.Results: We report on 39 patients, including 22 with obstetric detail available. The mean and median age was 33 years, range 24–45 years. Rheumatic disease diagnoses included rheumatoid arthritis (n = 9), systemic lupus erythematosus (n = 9), psoriatic arthritis/other inflammatory arthritides (n = 8), and antiphospholipid syndrome (n = 6). Most had a term birth (16/22), with 3 preterm births, 1 termination, and 1 miscarriage; 1 woman had yet to deliver at the time of report. One-quarter (n = 10/39) of pregnant women were hospitalized following COVID-19 diagnosis. Two of 39 (5%) required supplemental oxygen (both hospitalized); no patients died. The majority did not receive specific medication treatment for their COVID-19 (n = 32/39, 82%), and 7 patients received some combination of antimalarials, colchicine, anti–interleukin 1β, azithromycin, glucocorticoids, and lopinavir/ritonavir.Conclusion: Women with rheumatic diseases who were pregnant at the time of COVID-19 had favorable outcomes. These data have limitations due to the small size and methodology; however, they provide cautious optimism for pregnancy outcomes for women with rheumatic disease particularly in comparison to the increased risk of poor outcomes that have been reported in other series of pregnant women with COVID-19.

29 December 2021 in Journal of Osteoporosis
Verified
Journal Article
Open access
PDF file
BFBruno S. A. Ferreira
Bruno S. A. Ferreira
BCBernardo M. da Cunha
Bernardo M. da Cunha
LVLuciana P. Valadares
Luciana P. Valadares
LMLarissa A. Moreira
Larissa A. Moreira
FBFrederico G. A. Batista
Frederico G. A. Batista
SRSergio H. R. Ramalho
Sergio H. R. Ramalho
We aimed to evaluate characteristics associated with acute-phase response (APR) following first zoledronic acid infusion in a Brazilian cohort. This retrospective cohort study enrolled all adults with osteoporosis who underwent a first zoledronic acid infusion at our centre between June 2015 and June 2019. Clinical demographics (age, sex, diabetes, smoking, body mass index, and previous oral bisphosphonate use) and laboratory data (calcium, parathyroid hormone, renal function, and serum 25-hydroxyvitamin D and carboxy-terminal crosslinked telopeptide of type 1 collagen [CTX], both before and after infusion) were compared between patients with and without APR. We evaluated association magnitude between the presence of APR and clinical variables through logistic regression. This study enrolled 400 patients (women, 80%). APR was observed in 24.5% (n = 98) of patients. The mean symptom duration in days was 3.5 ± 2.8. Patients with APR were younger (67 ± 12 vs. 71 ± 11 years; ), used oral bisphosphonates less frequently (34% × 50%; ), and had greater baseline CTX (0.535 ng/mL [0.375, 0.697] × 0.430 [0.249, 0.681]; ) and ΔCTX (−69 [−76; −50] × −54 [−72; −23]; ) than those without APR. The other variables were similar between the groups. Only ΔCTX was associated (OR, 0.62; 95% CI 0.41–0.98) with APR after accounting for age and bisphosphonate use. APR occurred in 24.5% of the cohort. Younger age and absence of prior oral bisphosphonate use were associated with APR following first zoledronic acid infusion. APR was associated with ΔCTX (but no other variables) after adjusting for these factors.